Fasting and post-prandial splanchnic blood flow is reduced by a somatostatin analogue (octreotide) in man.

Cooper AM, Braatvedt GD, Qamar MI, Brown H, Thomas DM, Halliwell M, Read AE, Corrall RJ

Clinical science (London, England : 1979)1 Aug 1991Cited by 55 (Europe PMC)

PMID1653660DOI10.1042/cs0810169PepBankPUB-01653660

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialEfficacy outcome
In normal subjects, octreotide reduced fasting superior mesenteric artery flow by 59% (P less than 0.05).
In plain wordsIn normal subjects, octreotide reduced fasting superior mesenteric artery blood flow by 59%.
Peptide
Octreotide
Outcome
DecreaseFasting superior mesenteric artery flow
Study
n = 8
Outcome group
Splanchnic blood flow · Cardiovascular
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Fasting superior mesenteric artery blood flow reduction
59%
octreotide, fasting
p-value
< 0.05 p
fasting superior mesenteric artery blood flow
Source sentences
Summary
Octreotide reduced fasting superior mesenteric artery blood flow by 59% (P less than 0.05) and portal venous blood flow by 49% (P less than 0.01) and blunted the normal post-prandial rise.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of the subcutaneous administration of a long-acting somatostatin analogue (octreotide) or of placebo on the splanchnic blood flow response to a mixed solid meal has been examined in eight normal subjects by using a transcutaneous Doppler ultrasound technique.
Summary · context
Each subject was studied on two occasions more than 1 week apart.
Report a problemFND-0165366001
02HumanNon-randomized trialEfficacy outcome
In normal subjects, octreotide reduced fasting portal venous flow by 49% (P less than 0.01).
In plain wordsIn normal subjects, octreotide reduced fasting portal venous blood flow by 49%.
Peptide
Octreotide
Outcome
DecreaseFasting portal venous flow
Study
n = 8
Outcome group
Splanchnic blood flow · Cardiovascular
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Fasting portal venous blood flow reduction
49%
octreotide, fasting
p-value
< 0.01 p
fasting portal venous blood flow
Source sentences
Summary
Octreotide reduced fasting superior mesenteric artery blood flow by 59% (P less than 0.05) and portal venous blood flow by 49% (P less than 0.01) and blunted the normal post-prandial rise.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of the subcutaneous administration of a long-acting somatostatin analogue (octreotide) or of placebo on the splanchnic blood flow response to a mixed solid meal has been examined in eight normal subjects by using a transcutaneous Doppler ultrasound technique.
Summary · context
Each subject was studied on two occasions more than 1 week apart.
Report a problemFND-0165366002
03HumanNon-randomized trialEfficacy outcome
In normal subjects, octreotide blunted the normal postprandial splanchnic blood flow rise compared with the control response.
In plain wordsIn normal subjects, octreotide reduced the normal blood flow rise after a meal compared with the control response.
Peptide
Octreotide
Outcome
DecreasePostprandial splanchnic blood flow rise
Study
n = 8
Comparator
Placebo control day
Outcome group
Splanchnic blood flow · Cardiovascular
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Octreotide reduced fasting superior mesenteric artery blood flow by 59% (P less than 0.05) and portal venous blood flow by 49% (P less than 0.01) and blunted the normal post-prandial rise.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of the subcutaneous administration of a long-acting somatostatin analogue (octreotide) or of placebo on the splanchnic blood flow response to a mixed solid meal has been examined in eight normal subjects by using a transcutaneous Doppler ultrasound technique.
Summary · context
Each subject was studied on two occasions more than 1 week apart.
Report a problemFND-0165366003
04HumanNon-randomized trialEfficacy outcome
In normal subjects, pulse did not change after octreotide injection or meal ingestion.
In plain wordsIn normal subjects, pulse did not change after octreotide injection or a meal.
Peptide
Octreotide
Outcome
No significant changePulse
Study
n = 8
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Pulse and blood pressure did not change in response to either the injection or the ingestion of the meal.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of the subcutaneous administration of a long-acting somatostatin analogue (octreotide) or of placebo on the splanchnic blood flow response to a mixed solid meal has been examined in eight normal subjects by using a transcutaneous Doppler ultrasound technique.
Summary · context
Each subject was studied on two occasions more than 1 week apart.
Report a problemFND-0165366004
05HumanNon-randomized trialEfficacy outcome
In normal subjects, blood pressure did not change after octreotide injection or meal ingestion.
In plain wordsIn normal subjects, blood pressure did not change after octreotide injection or a meal.
Peptide
Octreotide
Outcome
No significant changeBlood pressure
Study
n = 8
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Pulse and blood pressure did not change in response to either the injection or the ingestion of the meal.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of the subcutaneous administration of a long-acting somatostatin analogue (octreotide) or of placebo on the splanchnic blood flow response to a mixed solid meal has been examined in eight normal subjects by using a transcutaneous Doppler ultrasound technique.
Summary · context
Each subject was studied on two occasions more than 1 week apart.
Report a problemFND-0165366005
06HumanNon-randomized trialEfficacy outcome
In normal subjects, octreotide suppressed insulin release in response to feeding compared with the control response.
In plain wordsIn normal subjects, octreotide suppressed insulin release after feeding compared with the control response.
Peptide
Octreotide
Outcome
DecreaseMeal-induced insulin release
Study
n = 8
Comparator
Placebo control day
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Octreotide suppressed the release of insulin, glucagon and pancreatic polypeptide in response to feeding and resulted in post-prandial hyperglycaemia.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of the subcutaneous administration of a long-acting somatostatin analogue (octreotide) or of placebo on the splanchnic blood flow response to a mixed solid meal has been examined in eight normal subjects by using a transcutaneous Doppler ultrasound technique.
Summary · context
Each subject was studied on two occasions more than 1 week apart.
Report a problemFND-0165366006
07HumanNon-randomized trialEfficacy outcome
In normal subjects, octreotide suppressed glucagon release in response to feeding compared with the control response.
In plain wordsIn normal subjects, octreotide suppressed glucagon release after feeding compared with the control response.
Peptide
Octreotide
Outcome
DecreaseMeal-induced glucagon release
Study
n = 8
Comparator
Placebo control day
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Octreotide suppressed the release of insulin, glucagon and pancreatic polypeptide in response to feeding and resulted in post-prandial hyperglycaemia.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of the subcutaneous administration of a long-acting somatostatin analogue (octreotide) or of placebo on the splanchnic blood flow response to a mixed solid meal has been examined in eight normal subjects by using a transcutaneous Doppler ultrasound technique.
Summary · context
Each subject was studied on two occasions more than 1 week apart.
Report a problemFND-0165366007
08HumanNon-randomized trialEfficacy outcome
In normal subjects, octreotide suppressed pancreatic polypeptide release in response to feeding compared with the control response.
In plain wordsIn normal subjects, octreotide suppressed pancreatic polypeptide release after feeding compared with the control response.
Peptide
Octreotide
Outcome
DecreaseMeal-induced pancreatic polypeptide release
Study
n = 8
Comparator
Placebo control day
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Octreotide suppressed the release of insulin, glucagon and pancreatic polypeptide in response to feeding and resulted in post-prandial hyperglycaemia.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of the subcutaneous administration of a long-acting somatostatin analogue (octreotide) or of placebo on the splanchnic blood flow response to a mixed solid meal has been examined in eight normal subjects by using a transcutaneous Doppler ultrasound technique.
Summary · context
Each subject was studied on two occasions more than 1 week apart.
Report a problemFND-0165366008
09HumanNon-randomized trialEfficacy outcome
In normal subjects, octreotide produced postprandial hyperglycaemia compared with the placebo control day.
In plain wordsIn normal subjects, octreotide produced high blood glucose after a meal compared with the placebo control day.
Peptide
Octreotide
Outcome
IncreasePostprandial hyperglycaemia
Study
n = 8
Comparator
Placebo control day
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Octreotide suppressed the release of insulin, glucagon and pancreatic polypeptide in response to feeding and resulted in post-prandial hyperglycaemia.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of the subcutaneous administration of a long-acting somatostatin analogue (octreotide) or of placebo on the splanchnic blood flow response to a mixed solid meal has been examined in eight normal subjects by using a transcutaneous Doppler ultrasound technique.
Summary · context
Each subject was studied on two occasions more than 1 week apart.
Report a problemFND-0165366009

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.